Skip to main content
    E

    Ensysce Biosciences Inc (ENSC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.38
    -0.03 (-6.28%)

    Market Cap: $7.97M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Ensysce Biosciences Inc (ENSC) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Ensysce Biosciences (ENSC) has a market cap of $7.97M. Its share count is up 530.38% from a year earlier. It holds $29.52M more cash than debt, 370.45% of its market cap.

    Total Valuation

    Market Cap$7.97M
    Latest price (Nov 17, 2026)$0.38

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 39.56% in the quarter ended Sep 30, 2026.

    Shares Outstanding18.19M
    Shares Change (YoY)+530.38%
    Shares Change (QoQ)+39.56%

    Valuation Ratios

    Sales and book value multiples are 1.1x and 0.3x.

    P/S Ratio1.1x
    Forward P/S1.7x
    P/B Ratio0.3x

    Price Statistics

    The stock is down 81.37% over 52 weeks and trades 13.64% below its 50-day average.

    Beta (1Y)1.33
    52-Week Change-81.37%
    1-Month Change-23.68%
    3-Month Change-1.08%
    6-Month Change+29.53%
    5-Year Change-99.99%
    Total Return (1Y)-81.37%
    Total Return (3Y CAGR)-69.53%
    Total Return (5Y CAGR)-85.51%
    Max Drawdown (1Y)-87.19%
    Max Drawdown (3Y)-98.97%
    Sharpe Ratio (1Y)-1.27
    Correlation with SPY (1Y)0.14
    50-Day Average$0.44
    200-Day Average$0.40
    52-Week Range$0.23 to $1.95
    RSI (14 Days)43.6
    Average Volume (20 Days)290.53K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 8.02x current liabilities, and total debt is 0.01x shareholder equity.

    Current Ratio8.02x
    Quick Ratio8.02x
    Debt / Equity0.01x
    Interest Coverage-899.84x

    Returns and Efficiency

    Return on invested capital is -32.90% over the last 12 months.

    Return on Assets (ROA)-294.02%
    Return on Invested Capital (ROIC)-32.90%
    Receivables Turnover26.85x
    Cash Conversion Cycle-98 days

    Scores

    ENSC has an Altman Z-Score of -9.20, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-9.20
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Balance Sheet

    Cash and Equivalents$29.67M
    Total Debt$154.87K
    Net Cash$29.52M
    Net Cash Per Share$1.62

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Growth

    Revenue grew 26.16% a year over 3 years.

    Revenue Growth (3Y CAGR)+26.16%
    Revenue Growth (5Y CAGR)+5.21%

    Revenue and profit by year

    Stock Splits

    The last split was a 1-for-15 reverse split on Dec 6, 2024.

    Last Split DateDec 6, 2024
    Split TypeReverse split
    Split Ratio1:15

    Analyst Forecast

    Consensus estimates put revenue growth at -19.56% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-19.56%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About ENSC

    What is ENSC's market cap?

    Ensysce Biosciences has a market cap of $7.97M.

    How many shares of ENSC are outstanding?

    Ensysce Biosciences has 18.19M shares outstanding. The count is up 530.38% from a year earlier.

    Does ENSC pay a dividend?

    No. Ensysce Biosciences does not pay a dividend.

    How much debt does ENSC have?

    Ensysce Biosciences has $154.87K of total debt and $29.67M of cash and equivalents, a net cash position of $29.52M.